GlobeNewswire

Employee communications leader Poppulo raises $35 million to accelerate global expansion

Del

Funding backs innovator shaping the future of workplace engagement

BOSTON, Jan. 09, 2019 (GLOBE NEWSWIRE) -- The world’s leading employee communications and engagement company, Poppulo, today announced an investment of $35 million by US-based Susquehanna Growth Equity (SGE).

Poppulo founder and CEO Andrew O’Shaughnessy said the investment will help the company accelerate international expansion plans in a sector that is now recognized as critical to business success.

“The companies and organizations who are winning know how absolutely crucial internal communication is not only for employee engagement but also in terms of recruitment and retention - and ultimately the bottom line,” said O’Shaughnessy.

Over 20% of the largest employers in the United States are Poppulo customers while the figure is even higher in Europe, at 30%.

Its customer base of over 800 of the world’s biggest organizations includes Unilever, Bank of America, Nestlé, Johnson Controls, Rolls-Royce, Boston Scientific - and almost half the world’s top pharma companies.

Commenting on SGE’s investment, Managing Director Jonathan Klahr, said: “Employee communications and engagement is tremendously important for business success and we view it as a market with enormous potential - a market led by the vision, ambition, and innovation of Poppulo.”

“We’re very excited about what we can achieve together, and how this investment will enable Andrew and his team to shape the sector’s future, as Poppulo escalates its global influence and expansion through best-in-class innovation and thought leadership,” said Mr. Klahr.

O'Shaughnessy said he was attracted by SGE's collaborative, entrepreneur-centric ethos and their scaling expertise. The investment will fund further market-leading innovation and R&D, plus expansion of sales and marketing across EMEA and the USA. Apart from initial seed capital the company has been bootstrapped up to now.

O’Shaughnessy founded Poppulo with the aim of creating the world’s most powerful force in employee communications and engagement: “In 2012 I clearly saw this was where we needed to be as a company, so I bet our future on a sector that was in early-stage development.”

“We were acutely aware that people need to feel a sense of purpose in their workplace, of being involved and being valued, and having their views heard and acted on. Which puts communications at the heart of everything a company needs to do if it is to be successful,” said O’Shaughnessy.

Poppulo - which has its North American head office in Boston and HQ in Cork, Ireland - pioneered specialist software for the internal communications sector, focusing initially on internal email management, enabling large organizations to communicate effectively with their workforces for greater levels of engagement and enhanced employee experience.

The company recently launched a mobile app which wraps the power of the platform’s email and analytics into an unrivaled employee communications solution. “The combination of our email and mobile products together with the power of our analytics is a game changer for the sector,” said O’Shaughnessy.

“We already dominate internal communications email globally, and now with our mobile app organizations can reach all their employees wherever they are, at their desks, at remote locations or on the road,” he said.

“Technology has completely changed the way we consume information and organizations have to ensure the digital experience of their employees in the workplace matches what they have grown to expect in their personal lives.”

“Internal communication has to be able to deliver a dialogue that is personalized and relevant to people who are used to filtering out irrelevant content in their lives outside of work. That’s where Poppulo comes in,” said O’Shaughnessy.

About Poppulo:

When many of the world’s most successful organizations - including GSK, Aon, Telefonica, Honda, and CDK Global - want to solve complex employee communication and engagement challenges with their large international workforces, they look to Poppulo.

Custom-built software designed for the internal communications sector enables organizations to plan, target, publish and measure the impact of their communications across multiple digital channels - email, mobile, video, social networks, all on one platform.

Just as easily, employee sentiment can quickly and regularly be assessed through pulse surveys using the same technology. For more information: poppulo.com

About SGE:

Susquehanna Growth Equity is an entrepreneur-centric growth equity fund with flexible capital and time horizons. We are focused on software, information services, and internet companies, and to date have invested over $1bn in market-leading companies such as Credit Karma, iCims, Payoneer and Outbrain.

All of our capital comes from Susquehanna International Group (SIG), one the world’s largest privately-held financial services firms. We are proud to be a part of one of the biggest bootstrapped, entrepreneurial success stories in the world. For more information: sgep.com

For further information contact:

Tim Vaughan
tvaughan@poppulo.com +353 21 2427277

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00Pressemelding

BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t

CCI has been retained by Waterloo Brewing to obtain Cannabis Licence16.1.2019 16:00Pressemelding

TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce they have partnered with Waterloo Brewing to help them obtain their Research and standard Processing Licence to develop cannabis-infused beverages. “CCI is working with Waterloo Brewing on the early stages of the application process and we are confident that we will help them achieve their desired licenses in time to be an active player in this growing sector of the cannabis industry”, said Brian Wagner, CEO and Founder, Cannabis Compliance Inc. “We are here to guide our clients through the early stages of the licensing process and for the many Health Canada requirements thereafter.” CCI offers end to end business solutions for cannabis companies large and small. Our team brings with them years of experience in the quality, regulatory, security and cultivation sectors, and supports manufacturers and retailers through regulatory challenges. As the world’s largest and mos

Aryaka Announces Expansion of Senior Leadership Team with New Chief Revenue Officer, Chief Transformation Officer and Chief Marketing Officer16.1.2019 15:00Pressemelding

Karen Freitag, Michelle Owczarzak, & Shashi Kiran join Aryaka to address significant growth and assist global enterprises in adopting managed connectivity as-a-service SAN MATEO, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aryaka®, announced today the appointment of several new executive hires to the company’s leadership team, including Karen Freitag (Chief Revenue Officer), Michelle Owczarzak (Chief Transformation Officer), and Shashi Kiran (Chief Marketing Officer). “Connectivity is the lifeblood of the global enterprise and Aryaka is the industry benchmark for secure managed connectivity worldwide. We are excited to have experienced industry veterans join our robust executive leadership team and continue to help build upon the immense success and growth that Aryaka has seen in recent years,” said Matt Carter, CEO of Aryaka. “As our customers expand globally, embrace SD-WAN, or move to the cloud, we’re becoming the de facto choice for their needs to make this happen better, faster, che

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors16.1.2019 07:00Pressemelding

Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated

GSA Europe’s Managing Director Elected Co-lead of CEN’s TC456 Committee15.1.2019 21:12Pressemelding

SAN GWANN, Malta, Jan. 15, 2019 (GLOBE NEWSWIRE) -- GSA Europe’s Managing Director Mark Pace has been elected by the Comité Européen de Normalisation (CEN) to lead the creation of a European Union online gaming reporting standard. CEN has established Technical Committee 456 to create this standard in support of online gambling supervision. GSA Europe joined Technical Committee 456 as a Liaison Organization in 2017. The Technical Committee’s mandate from the European Commission is directly aligned with work that GSA Europe has already started, namely, to create a single standard set of data elements and single standard way in which data is provided by online gambling providers to EU Member State regulatory authorities. In addition to joining and now leading the Technical Committee’s work, GSA Europe also donated their draft Regulatory Data Set and Regulatory Reporting Interface to CEN seeking to help jump-start the Committee’s work. “Joining CEN’s TC456 as a Liaison Organization, and no

Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study15.1.2019 15:00Pressemelding

OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05). “There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist